Interestingly, in univariable analysis, higher FTO expression associated with better overall and progression free survival both in ccRCC and pRCC patients, whereas no associations were disclosed concerning ALKBH5 expressions levels (Supplementary Tables S2–S4 and Supplementary Figure S1). This evidence concerns the gene ALKBH5 and nonpapillary renal cell carcinoma.